Historical Valuation
Amicus Therapeutics Inc (FOLD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.13 is considered Undervalued compared with the five-year average of 4.88. The fair price of Amicus Therapeutics Inc (FOLD) is between 21.81 to 30.76 according to relative valuation methord. Compared to the current price of 14.28 USD , Amicus Therapeutics Inc is Undervalued By 34.52%.
Relative Value
Fair Zone
21.81-30.76
Current Price：14.28
34.52%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Amicus Therapeutics Inc (FOLD) has a current Price-to-Book (P/B) ratio of 19.11. Compared to its 3-year average P/B ratio of 21.50 , the current P/B ratio is approximately -11.15% higher. Relative to its 5-year average P/B ratio of 18.20, the current P/B ratio is about 5.00% higher. Amicus Therapeutics Inc (FOLD) has a Forward Free Cash Flow (FCF) yield of approximately 0.22%. Compared to its 3-year average FCF yield of -2.33%, the current FCF yield is approximately -109.46% lower. Relative to its 5-year average FCF yield of -4.15% , the current FCF yield is about -105.30% lower.
P/B
Median3y
21.50
Median5y
18.20
FCF Yield
Median3y
-2.33
Median5y
-4.15
Competitors Valuation Multiple
AI Analysis for FOLD
The average P/S ratio for FOLD competitors is 25.20, providing a benchmark for relative valuation. Amicus Therapeutics Inc Corp (FOLD.O) exhibits a P/S ratio of 6.13, which is -75.67% above the industry average. Given its robust revenue growth of 19.46%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for FOLD
1Y
3Y
5Y
Market capitalization of FOLD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of FOLD in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is FOLD currently overvalued or undervalued?
Amicus Therapeutics Inc (FOLD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 6.13 is considered Undervalued compared with the five-year average of 4.88. The fair price of Amicus Therapeutics Inc (FOLD) is between 21.81 to 30.76 according to relative valuation methord. Compared to the current price of 14.28 USD , Amicus Therapeutics Inc is Undervalued By 34.52% .
What is Amicus Therapeutics Inc (FOLD) fair value?
FOLD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Amicus Therapeutics Inc (FOLD) is between 21.81 to 30.76 according to relative valuation methord.
How does FOLD's valuation metrics compare to the industry average?
The average P/S ratio for FOLD's competitors is 25.20, providing a benchmark for relative valuation. Amicus Therapeutics Inc Corp (FOLD) exhibits a P/S ratio of 6.13, which is -75.67% above the industry average. Given its robust revenue growth of 19.46%, this premium appears unsustainable.
What is the current P/B ratio for Amicus Therapeutics Inc (FOLD) as of Jan 10 2026?
As of Jan 10 2026, Amicus Therapeutics Inc (FOLD) has a P/B ratio of 19.11. This indicates that the market values FOLD at 19.11 times its book value.
What is the current FCF Yield for Amicus Therapeutics Inc (FOLD) as of Jan 10 2026?
As of Jan 10 2026, Amicus Therapeutics Inc (FOLD) has a FCF Yield of 0.22%. This means that for every dollar of Amicus Therapeutics Inc’s market capitalization, the company generates 0.22 cents in free cash flow.
What is the current Forward P/E ratio for Amicus Therapeutics Inc (FOLD) as of Jan 10 2026?
As of Jan 10 2026, Amicus Therapeutics Inc (FOLD) has a Forward P/E ratio of 59.81. This means the market is willing to pay $59.81 for every dollar of Amicus Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Amicus Therapeutics Inc (FOLD) as of Jan 10 2026?
As of Jan 10 2026, Amicus Therapeutics Inc (FOLD) has a Forward P/S ratio of 6.13. This means the market is valuing FOLD at $6.13 for every dollar of expected revenue over the next 12 months.